Clik here to view.
Top pedigree leading Xcovery’s kinase inhibitors
With two leading biotech entrepreneurs and scientists at the helm, closely held Xcovery Holdings has a leg up as it continues development of next generation kinase inhibitors as treatments for cancer...
View ArticleClik here to view.
Analysts initiate coverage of Ophthotech
Analysts with Leerink Swann and Stifel Nicholas have initiated coverage of Ophthotech (NASDAQ:OPHT), citing the potential vision benefits the company’s Fovista treatment for the wet form of age-related...
View ArticleClik here to view.
Mati Therapeutics isn’t your traditional biotech startup
Not quite two years old yet, closely held Mati Therapeutics is conducting a pre-Phase 3 clinical trial with an ocular punctal plug delivery system (PPDS) that could become a preferred alternative to...
View ArticleClik here to view.
QLT to merge into Auxilium Pharma
One of Canada’s iconic drug developers, QLT (NASDAQ:QLTI; TSX:QLT), which developed the first treatment for wet age-related macular degeneration, is disappearing through a merger with Auxilium...
View ArticleClik here to view.
WB starts Avalanche Biotechnologies at outperform
William Blair has launched coverage of Avalanche Biotechnologies (NASDAQ:AAVL) with an “outperform” rating and $52 price target. The stock closed at $30.52 on Friday. “Avalanche is a potentially...
View ArticleClik here to view.
Eyes on Ohr Pharma wet AMD study
Even though Ohr Pharmaceutical (OTCBB:OHRP) will be releasing results, in the current quarter, of a Phase 2 clinical trial in patients with cancer cachexia, all eyes are on a Phase 2 study of its...
View ArticleClik here to view.
Ocular Therapeutix eyeing sustained drug delivery
Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic...
View ArticleClik here to view.
Ohr Pharma stock tumbles on Phase 2 trial results
Ohr Pharmaceutical’s (NASDAQ:OHRP) experimental eye drug failed the main goal as a combination therapy in a mid-stage study, sending the company’s shares plunging 67% in the afternoon session on...
View ArticleClik here to view.
Maxim starts RestorGenex at buy
Maxim Group has initiated coverage of RestorGenex (OTC:RESX) with a “buy” rating and $6 price target. The stock closed at $2.70 on Monday. “We believe the company’s two-core proprietary technologies,...
View ArticleClik here to view.
Molecular Partners continues to validate DARPin platform
Molecular Partners’ blockbuster expansion last month of an existing alliance with Allergan (NYSE:AGN) has added to the growing appeal of the closely held Swiss-based drug developer and the type of...
View Article
